Mechanistically, the limited evidence available suggests that TMED3 worked through positive modulation of WNT-TCF [11] and IL-11/STAT3 [12] signaling pathways in colon and hepatocellular carcinoma, respectively. Here, IL11 is linked to hepatocellular carcinoma.